These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32598610)

  • 1. [Analysis of the impact of vaccination of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes].
    Ignatova GL; Blinova EV; Antonov VN; Grebneva IV
    Ter Arkh; 2019 Nov; 91(11):49-54. PubMed ID: 32598610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with type 2 diabetes mellitus].
    Ignatova GL; Blinova EV; Antonov VN
    Ter Arkh; 2022 Jan; 94(1):100-106. PubMed ID: 36286924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of compliance dynamics in patients with chronic obstructive pulmonary disease on the background of vaccination against pneumococcal infection.
    Jgnatova GL; Antonov VN
    Ter Arkh; 2018 Apr; 90(3):47-52. PubMed ID: 30701856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study.
    Ignatova GL; Avdeev SN; Antonov VN
    Sci Rep; 2021 Aug; 11(1):15948. PubMed ID: 34354113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the effectiveness of joint or sequential vaccination with pneumococcal and influenza vaccines in patients with chronic obstructive pulmonary disease].
    Ignatova GL; Antonov VN; Blinova EV
    Ter Arkh; 2019 Aug; 91(8):12-17. PubMed ID: 32598748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of vaccine prophylaxis concentrated pneumococcal vaccine in patients with chronic obstructive lung disease and chronic heart failure.
    Ignatova GL; Antonov VN
    Ter Arkh; 2018 Aug; 90(8):53-62. PubMed ID: 30701949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease].
    Protasov AD; Zhestkov AV; Kostinov MP; Shteiner ML; Tezikov YV; Lipatov IS; Yastrebova NE; Kostinova AM; Ryzhov AA; Polishchuk VB
    Ter Arkh; 2017; 89(12. Vyp. 2):165-174. PubMed ID: 29488477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Choice of optimal vaccination tactics against pneumococcal infection from immunological and clinical standpoints in patients with chronic obstructive pulmonary disease].
    Protasov AD; Kostinov MP; Zhestkov AV; Shteiner ML; Magarshak OO; Kostinova TA; Ryzhov AA; Pakhomov DV; Blagovidov DA; Panina MI
    Ter Arkh; 2016; 88(5):62-69. PubMed ID: 27239929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
    Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
    Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of exacerbation and pneumonia before and after conjugated pneumococcal vaccination in patients with chronic obstructive pulmonary disease, and the effect of inhaled corticosteroid use on results.
    Vayısoğlu Şahin G; Karadeniz G; Polat G; Yalnız E; Ayrancı A; Demirci Üçsular F; Güçsav MO
    Tuberk Toraks; 2022 Jun; 70(2):149-156. PubMed ID: 35785879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 13-valent pneumococal conjugate polysaccharide vaccination in exacerbations rate of COPD patients with moderate to severe obstruction.
    Figueira-Gonçalves JM; Bethencourt-Martín N; Pérez-Méndez LI; Díaz-Pérez D; Guzmán-Sáenz C; Viña-Manrique P; Pedrero-García AJ
    Rev Esp Quimioter; 2017 Aug; 30(4):269-275. PubMed ID: 28585796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.
    Walters JA; Smith S; Poole P; Granger RH; Wood-Baker R
    Cochrane Database Syst Rev; 2010 Nov; (11):CD001390. PubMed ID: 21069668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal vaccination and chronic respiratory diseases.
    Froes F; Roche N; Blasi F
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3457-3468. PubMed ID: 29255353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.
    Granger R; Walters J; Poole PJ; Lasserson TJ; Mangtani P; Cates CJ; Wood-Baker R
    Cochrane Database Syst Rev; 2006 Oct; (4):CD001390. PubMed ID: 17054135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on the effectiveness of the pneumococcal vaccination in patients with chronic obstructive pulmonary disease].
    Wu YX; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Apr; 45(4):404-409. PubMed ID: 35381638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of influenza and 23-valent pneumococcal polysaccharide vaccinations on elderly with chronic obstructive pulmonary diseases: a community-based intervention study].
    Wen Y; He L; Zhai Y; Wu J; Chen YY; Wang H; Zong QQ; Liang XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Jun; 39(6):792-798. PubMed ID: 29936749
    [No Abstract]   [Full Text] [Related]  

  • 18. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
    Gouveia M; Jesus G; Inês M; Costa J; Borges M
    Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.